Phio Pharmaceuticals Corp (PHIO)

[sabaidii2]

A reverse split is not the problem. Money needed to stay alive (ie, equity raise / dilution) is the problem.

At a Market Cap of, say, $15 million, obtaining a similar amount to fund one year's worth of operation will be ruinous to shareholders. That's why lack of meaningful insider share purchases on the open market is such a big red flag. Well, that plus Geert's obscene $600K salary (up from a mere outrageous $500K last year).

The way I see things, near-term possible $ deals are:

1) Samcyprone - Likely as past phase 2 test results are pretty good

2) RXI-231 (skin lightener) - Status is unknown and it's only one month into an expected 3-4 month test study. IF it works well, RXI could easily soon have a $billion market cap. If not, not good.

3) Immuno-oncology - No way to handicap this. I'm pessimistic until after a mentioned 2018 Phase 1 test.